Stay Ahead of Wall Street. Find out what is happening to Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) stock today? Its price is jumping 3.05 points, trading at $116.95 levels, and is up 2.67% from its previous close of $113.9. The shares seem to have an active trading volume day with a reported 282496 contracts so far this session. ICPT shares had a relatively better volume day versus average trading capacity of 547.63 thousand shares, but with a 25.67 million float and a 18.23% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for ICPT stock indicates that the average analyst price target is $147.11 per share. This means the stock has a potential increase of 25.79% from where the ICPT share price has been trading recently which is between $110 and $113.99. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $85. Flipping the other side of the coin, an analyst who is fully bullish set a price target as high as $257.
During the recent trading session for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), the company witnessed their stock rise $15.15 over a week and surge $42.12 from the price 20 days ago. When compared to their established 52-week high of $131.87, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 02/19/19. The recent low of $56.76 stood for a -11.32% since 10/10/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 1.48 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to. At the moment, the median target price for ICPT is set at $147, a figure which is above the recent 1-year high the stock witnessed.
Looking at the current readings for Intercept Pharmaceuticals, Inc., the two-week RSI stands at 92.03. This figure suggests that ICPT stock, for now, is oversold, meaning that the shares are not stable in terms of price movement. The stochastic readings, on the other hand, based on the current ICPT readings is similarly very revealing as it has a stochastic reading of 97.31% at this stage. This figure means that ICPT share price today is being oversold.
Technical chart claims that Intercept Pharmaceuticals, Inc. (ICPT) would settle between $115.26/share to $116.62/share level. However, if the stock price goes below the $111.27 mark, then the market for Intercept Pharmaceuticals, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $108.64 for its downside target. The stock is currently in the green zone of MACD, with the indicator reading 10.39. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at Canaccord Genuity, assumed coverage of ICPT assigning Buy rating, according to their opinion released on December 02. Citigroup analysts bumped their rating on Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) stock from Neutral to Buy in a separate flash note issued to investors on September 04. Analysts at Stifel, made their first call for the equity with a Hold recommendation, according to a research note that dated back to June 25.
ICPT equity has an average rating of 2.15, with the figure leaning towards a bullish end. 18 analysts who tracked the company were contacted by Reuters. Amongst them, 1 rated the stock as a hold while the remaining 17 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while others rated it as a sell. 16 analysts rated Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) as a buy or a strong buy while 1 advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Intercept Pharmaceuticals, Inc. (ICPT)’s current-quarter revenues are projected to climb by nearly 29.2% to hit $68.84 million, based on current consensus estimate. The firm’s full-year revenues are expected to expand by over 38.6% from $179800 to a noteworthy $249140. At the other end of the current quarter income statement, Intercept Pharmaceuticals, Inc. is expected to see its adjusted earnings surge by roughly 12.1% to hit $-2.61 per share. For the fiscal year, ICPT’s earnings are projected to climb by roughly 4.5% to hit $-10.37 per share.